Company / Accounts Receivable
Biofrontera Inc. Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$7.3M
FY2025
5-year range
$3.7M / $7.3M
FY2021-FY2025
Trend
+37.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 3 consecutive years, from $4M in FY2022 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 3-year CAGR of +24.8%.
Improved from $5M to $7M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +24.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Biofrontera Inc.'s accounts receivable has grown for 3 consecutive years.
- 3-year CAGR of +24.8%, indicating consistent growth.
- In FY2025, accounts receivable increased 37.2% year-over-year.
- Lowest accounts receivable in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.3M | +37.2% |
| FY2024 | $5.3M | +3.0% |
| FY2023 | $5.2M | +37.7% |
| FY2022 | $3.7M | -1.0% |
| FY2021 | $3.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026